|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
118,790,000 |
Market
Cap: |
42.71(M) |
Last
Volume: |
19,275,386 |
Avg
Vol: |
9,025,204 |
52
Week Range: |
$0.3595 - $0.3595 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Novavax is a biotechnology company that promotes improved global health through the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Co.'s vaccine candidates, including both its coronavirus vaccine candidate, NVX-CoV2373, and its primary influenza vaccine candidate, NanoFlu, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 and NanoFlu include the use of Co.'s proprietary Matrix-M adjuvant.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
6,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$43,042 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-01-21 |
2023-10-20 |
2023-04-21 |
2022-04-21 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hahn Timothy Jon |
SVP, Manufacturing & PDOfficer |
|
2011-09-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,000 |
|
- |
|
Evans Gray C |
Director |
|
2011-08-23 |
4/A |
S |
$1.22 |
$581,423 |
D/D |
(476,576) |
773,878 |
|
- |
|
Evans Gray C |
Director |
|
2011-08-22 |
4/A |
S |
$1.25 |
$268,500 |
D/D |
(214,800) |
1,250,454 |
|
- |
|
Erck Stanley C |
President and CEO |
|
2011-08-19 |
4 |
B |
$1.26 |
$16,380 |
D/D |
13,000 |
13,000 |
2.81 |
- |
|
Erck Stanley C |
President and CEO |
|
2011-08-10 |
4 |
B |
$1.24 |
$20,524 |
D/D |
16,552 |
16,552 |
2.81 |
- |
|
Erck Stanley C |
President and CEO |
|
2011-08-09 |
4 |
B |
$1.24 |
$41,476 |
D/D |
33,448 |
33,448 |
2.81 |
- |
|
Trizzino John |
Snr. VP, Int & Govt Alliances |
|
2011-08-09 |
4 |
B |
$1.18 |
$23,800 |
D/D |
20,000 |
10,000 |
2.74 |
- |
|
Driscoll Frederick W |
VP, CFO & Treasurer |
|
2011-08-09 |
4 |
B |
$1.18 |
$23,600 |
D/D |
20,000 |
20,000 |
2.74 |
- |
|
Douglas Richard |
Director |
|
2011-08-09 |
4 |
B |
$1.20 |
$60,000 |
D/D |
50,000 |
50,000 |
2.39 |
- |
|
Evans Gray C |
Director |
|
2011-06-23 |
4 |
S |
$1.22 |
$581,423 |
D/D |
(476,576) |
773,878 |
|
- |
|
Evans Gray C |
Director |
|
2011-06-22 |
4 |
S |
$1.25 |
$268,500 |
D/D |
(214,800) |
1,250,454 |
|
- |
|
Douglas Richard |
Director |
|
2011-06-20 |
4 |
B |
$2.04 |
$101,750 |
D/D |
50,000 |
50,000 |
2.39 |
- |
|
Glenn Gregory M |
Chief Scientific Officer |
|
2011-04-07 |
4 |
S |
$2.56 |
$133,120 |
D/D |
(52,000) |
414,000 |
|
- |
|
Glenn Gregory M |
Chief Scientific Officer |
|
2010-08-25 |
4 |
B |
$2.01 |
$4,018 |
D/D |
2,000 |
2,000 |
2.66 |
- |
|
Glenn Gregory M |
Chief Scientific OfficerOffice |
|
2010-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
50,000 |
|
- |
|
Thornton Mark Owens |
SVP & Chief Medical OfficerOff |
|
2010-05-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,000 |
|
- |
|
Lambert John A |
Director |
|
2009-07-02 |
4 |
S |
$2.76 |
$98,002 |
D/D |
(34,746) |
80,000 |
|
- |
|
Singhvi Rahul |
President, CEO |
|
2009-07-02 |
4 |
S |
$3.00 |
$150,000 |
D/D |
(50,000) |
113,104 |
|
- |
|
Hage Raymond Joseph |
Sr. VP. Commercial Operations |
|
2009-07-02 |
4 |
S |
$2.79 |
$465,175 |
D/D |
(162,022) |
11,512 |
|
- |
|
Hage Raymond Joseph |
Sr. VP. Commercial Operations |
|
2009-07-02 |
4 |
OE |
$0.74 |
$74,000 |
D/D |
100,000 |
173,534 |
|
- |
|
Heaton Penny |
VP & Chief Medical Officer |
|
2009-07-02 |
4 |
S |
$2.86 |
$23,832 |
D/D |
(8,333) |
18,667 |
|
- |
|
Singhvi Rahul |
President, CEO |
|
2009-07-01 |
4 |
S |
$2.88 |
$622,856 |
D/D |
(208,334) |
163,104 |
|
- |
|
Singhvi Rahul |
President, CEO |
|
2009-07-01 |
4 |
OE |
$0.74 |
$111,000 |
D/D |
150,000 |
371,438 |
|
- |
|
Hage Raymond Joseph |
Sr. VP. Commercial Operations |
|
2009-07-01 |
4 |
S |
$3.07 |
$19,273 |
D/D |
(6,261) |
5,251 |
|
- |
|
Johnston Thomas Scott |
Vice President, Strategy |
|
2009-07-01 |
4 |
S |
$3.05 |
$45,878 |
D/D |
(15,000) |
11,000 |
|
- |
|
152 Records found
|
|
Page 3 of 7 |
|
|